The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Clinical Cancer Research|2015Cited by 18
Endothelial Injury Following CAR-T Cell Immunotherapy for Hematological MalignanciesChristos Demosthenous, Eleni Gavriilaki, Paschalis Evangelidis et al.|Cancers|2025Cited by 13
Expression of the activation markers Blimp1, Foxp1 and pStat3 in extranodal diffuse large B-cell lymphomas.Georgios Petrakis, Nicolas Papadopoulos, Ioannis Kostopoulos et al.|PubMed|2017Cited by 4
CD4+ T Cells in High-Risk MDS Patients Bear an Aberrant STAT Signaling BiosignatureEleftheria Lamprianidou, Ιoannis Kotsianidis, Constantinos Tsatalas et al.|Blood|2014Cited by 1
Supplementary Table S2 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Unknown|2023Cited by 0